The following article (written by Rafeal Dal-Re, Michael Bracken & John Ioannidis in the BMJ) is a timely reminder to authors, journalists and consumers about the pros and cons of non-regulated interventions and trials. Efforts to promote the availability of data from clinical trials have been led predominantly by regulators (EMA, 2014) or drug companies… Read More